Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 801–900 of 1,026
Liu, H.-J., Lizotte, P. H., Du, H., Speranza, M. C., Lam, H. C., Vaughan, S. W., Alesi, N., Wong, K., Freeman, G. J., Sharpe, A. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98674 · Cited by 78
Application of NanoString technologies in companion diagnostic development
Eastel, J. M., Lam, K. W., Lee, N. L., Lok, W. Y., Tsang, H. F., Pei, X. M., Chan, A. K. C., Cho, W. C. S., & Wong, S. C. C. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1623672 · Cited by 74
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Kwon, M., Jung, H., Nam, G., & Kim, I.-S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.009 · Cited by 78
Sheng, W., Liu, Y., Chakraborty, D., Debo, B. M., & Shi, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0017 · Cited by 78
“We then interrogated a list of individual genes with well-documented roles in suppressing T cell immunity directly or indirectly through dendritic cells (DCs) (10, 20, 21), with two filtering criteria: 1) gene transcripts were reliably detected in LSD1-deficient B16 tumor cells (logCPM > 1) and 2) gene expression was…”
BackgroundCytosolic Delivery of Thiolated Mn‐cGAMP Nanovaccine to Enhance the Antitumor Immune Responses
Chen, C., Tong, Y., Zheng, Y., Shi, Y., Chen, Z., Li, J., Liu, X., Zhang, D., & Yang, H. (2021) · Small · doi:10.1002/smll.202006970 · Cited by 74
Relationship between Th17 immune response and cancer
Marques, H. S., de Brito, B. B., da Silva, F. A. F., Santos, M. L. C., de Souza, J. C. B., Correia, T. M. L., Lopes, L. W., Neres, N. S. D. M., Dórea, R. S. D. M., Dantas, A. C. S., et al. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.845 · Cited by 87
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Srour, N., Villarreal, O. D., Hardikar, S., Yu, Z., Preston, S. E. J., Miller, W. H., Szewczyk, M. M., Baršytė-Lovejoy, D., Xu, H., Chen, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110582 · Cited by 76
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy
Zeng, Q., Liu, M., Wang, Z., Zhou, R., & Ai, K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02366-y · Cited by 94
“…activation of a comprehensive cancer-immunity cycle, encompassing the release and presentation of cancer antigens, the priming and activation of T cells, the trafficking and infiltration of T cells into tumor tissue, and the subsequent recognition and elimination of cancer cells by T cells [3, 4].”
Kimmel, B. R., Arora, K., Chada, N. C., Bharti, V., Kwiatkowski, A. J., Finkelstein, J. E., Hanna, A., Arner, E. N., Sheehy, T. L., Pastora, L. E., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01400-0 · Cited by 86
Advancing Cancer Immunotherapies with Nanotechnology
Lou, J. W. H., Zhang, L., & Zheng, G. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800128 · Cited by 78
Yu, S., Sha, H., Qin, X., Chen, Y., Li, X., Shi, M., & Feng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1182-y · Cited by 71
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy
Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69
Zhu, L., Wu, W., Jiang, S., Yu, S., Yu, Y., Wang, K., He, J., Ren, Y. T., & Wang, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569887 · Cited by 75
Exhausted T cells and epigenetic status
Zeng, Z., Wei, F., & Ren, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0338 · Cited by 78
Wang, Y., Wang, Z., Chen, B., Yin, Q., Pan, M., Xia, H., Zhang, B., Yan, Y., Jiang, Z., Zhang, Q., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00977 · Cited by 69
Wang, X., Chen, Y., Li, Z., Huang, B., Xu, L., Lai, J., Lu, Y., Zha, X., Liu, B., Lan, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202101447 · Cited by 78
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 74
Zhan, M., Yu, X., Zhao, W., Peng, Y., Peng, S., Li, J., & Lu, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01226-3 · Cited by 74
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy
Ban, W., Guan, J., Huang, H., He, Z., Sun, M., Liu, F., & Sun, J. (2022) · Nano Research · doi:10.1007/s12274-021-4031-6 · Cited by 75
“| www.editorialmanager.com/nare/default.asp brain metastases despite stereotactic RT and dual CTLA-4/PD-1 blocking (ipilimumab/nivolumab).”
BackgroundQian, K., Fu, W., Li, T., Zhao, J., Lei, C., & Hu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02492-1 · Cited by 79
Xiao, J., Sun, F., Wang, Y., Лю, Б., Zhou, P., Wang, F., Zhou, H., Ge, Y., Yue, T., Luo, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci158352 · Cited by 72
“Immune checkpoint blockade (ICB) of PD-1/PD-L1 and CTLA-4 could reinvigorate cytotoxic CD8+ T cells in the TME and dampen tumor progression in numerous types of cancers (3).”
BackgroundProgress in the cryoablation and cryoimmunotherapy for tumor
Chen, Z., Meng, L., Zhang, J., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094009 · Cited by 85
“By blocking the corresponding immune checkpoint signaling pathways, the activation and proliferation of T cells can be restored and the anti-tumor immune response can be enhanced (77).”
BackgroundGlutathione‐Induced In Situ Michael Addition between Nanoparticles for Pyroptosis and Immunotherapy
Zhen, W., Liu, Y., An, S., & Jiang, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301866 · Cited by 71
Nadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 78
“Although NSCLC may have a high mutational load or PD-L1 expression, which are associated with response to antiPD(L)1 therapy, many patients do not respond to single agent anti-PD(L)1 inhibition [11, 12].”
BackgroundMultilevel Mechanisms of Cancer Drug Resistance
Roszkowska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212402 · Cited by 86
“Additionally, the accumulation of immunosuppressive metabolites and altered oxygen availability further compromise immune cell function [165].”
Potentiating prostate cancer immunotherapy with oncolytic viruses
Lee, P. C., & Gujar, S. A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.10 · Cited by 73
Claret, L., Jin, J. Y., Ferté, C., Winter, H. R., Girish, S., Stroh, M., He, P., Ballinger, M. D., Sandler, A. B., Joshi, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3662 · Cited by 71
CAR ‐T cell therapy in melanoma: A future success story?
Simon, B., & Uslu, U. (2018) · Experimental Dermatology · doi:10.1111/exd.13792 · Cited by 80
Buss, C. G., & Bhatia, S. N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001569117 · Cited by 70
“The reasons for this limitation remain an area of great interest and active investigation (5), though emerging evidence suggests tumor mutational burden, often driven by microsatellite instability, can predict responsiveness to these treatments (6).”
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 71
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Ott, P. A., & Wu, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1357 · Cited by 72
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., Grenda, A., Krawczyk, P. A., & Milanowski, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081915 · Cited by 79
“However, there are many more molecules that stimulate or inhibit the function of lymphocytes in the immune synapse [18,19].”
BackgroundImmunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 73
Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy
Ruan, S., Greenberg, Z., Pan, X., Zhuang, P., Erwin, N., & He, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100650 · Cited by 70
Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.
Ginckels, P., & Holvoet, P. (2022) · Lirias (KU Leuven) · Cited by 100
Cancer biology deciphered by single-cell transcriptomic sequencing
Li, Y., Jin, J., & Bai, F. (2021) · Protein & Cell · doi:10.1007/s13238-021-00868-1 · Cited by 88
“It has been increasingly recognized that non-malignant cellular components of the TME, including diverse subsets of lymphocytes, myeloid cells, stromal cells, other resident host cells, and their secreted factors, have a significant impact on cancer progression and treatment outcomes (Chen and Mellman, 2017; Maman and…”
BackgroundInfluentialImmunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
Fang, P., Zhou, J., Liang, Z., Yang, Y., Luan, S., Xiao, X., Li, X., Zhang, H., Shang, Q., Zeng, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975986 · Cited by 73
“During prolonged exposure to a tumor antigen, T cells upregulate negative regulators such as PD-1, leading to the i r funct iona l exhaust ion (14) .”
BackgroundNavigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Organoids to study immune functions, immunological diseases and immunotherapy
Ye, W., Luo, C., Li, C., Huang, J., & Liu, F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.027 · Cited by 67
Cytokines in oncolytic virotherapy
Pol, J. G., Workenhe, S. T., Konda, P., Gujar, S. A., & Kroemer, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.007 · Cited by 75
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 67
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Uruga, H., & Mino-Kenudson, M. A. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03030-8 · Cited by 73
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
Almangush, A., Leivo, I. V. V., & Mäkitie, A. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.616629 · Cited by 76
“In order to predict cancer response to immunotherapy, recent research (21) has tried to identify the immune profile of tumors classified into cold tumor (also known as immune desert) or hot tumor (also known as inflamed tumor).”
BackgroundChen, L., Chen, H., Ye, J., Ge, Y., Wang, H., Dai, E., Ren, J., Liu, W., Ma, C., Ju, S., et al. (2021) · Theranostics · doi:10.7150/thno.56494 · Cited by 69
“However, the majority of solid tumors are defined as “cold” or “immune-desert” tumors [2-4].”
BackgroundHomologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
van Wilpe, S., Tolmeijer, S. H., Koornstra, R. H. T., de Vries, I. J. M., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2021) · Cancers · doi:10.3390/cancers13092249 · Cited by 82
“While a uniform definition of immunogenicity is lacking, a high number of tumor-infiltrating lymphocytes (TILs), especially of CD8+ T cells, is commonly considered indicative of immunogenicity [50].”
BackgroundSingle-Cell Analysis of the Pan-Cancer Immune Microenvironment and scTIME Portal
Hong, F., Meng, Q., Zhang, W., Zheng, R., Li, X., Cheng, T., Hu, D., & Gao, X. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-1026 · Cited by 73
“In addition to the immune cells, the molecular features of tumor cells, cancer-associated fibroblasts (CAF), and the ECM orchestrate a highly variable TIME (9, 48).”
BackgroundTargeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Wang, D.-K., Zuo, Q., He, Q., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705999 · Cited by 74
“Third, tumors can upregulate the expression of PD-1 and PD-L1 to induce peripheral T cell depletion (77).”
BackgroundYuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C.-C., Zhang, M. S., Xue, H. D. G., Tse, A. P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.037 · Cited by 70
Sorin, M., Karimi, E., Rezanejad, M., Yu, M. W., Desharnais, L., McDowell, S. A. C., Doré, S., Arabzadeh, A., Breton, V., Fiset, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005545 · Cited by 90
Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
Hohtari, H. R., Brück, O. E., Blom, S., Turkki, R., Sinisalo, M., Kovanen, P. E., Kallioniemi, O., Pellinen, T. S., Porkka, K., & Mustjoki, S. M. (2019) · Leukemia · doi:10.1038/s41375-018-0360-1 · Cited by 74
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer
Chaib, M., Chauhan, S. C., & Makowski, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00351 · Cited by 67
“Immune cell involvement in inflammatory ailments has long been established; however, their role in cancer remained unappreciated until the past three decades (Chen and Mellman, 2017).”
BackgroundByrd, A. L., Liu, M., Fujimura, K. E., Lyalina, S., Nagarkar, D. R., Charbit, B., Bergstedt, J., Patin, E., Harrison, O. J., Quintana-Murci, L., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200606 · Cited by 63
Self-citationCurrent Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
Cesano, A., & Warren, S. E. (2018) · Biomedicines · doi:10.3390/biomedicines6010014 · Cited by 73
“Briefly, anticancer immunity in humans can be histologically segregated into three main phenotypes: the inflamed phenotype (also known as “hot”), the immune-excluded phenotype, and the immune-desert phenotype (the latter two considered “cold” tumours) [43].”
BackgroundSequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma
de Velasco, G., Bex, A., Albiges, L. K., Powles, T. B., Rini, B. I., Motzer, R. J., Heng, D. Y. C., & Escudier, B. J. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.06.022 · Cited by 69
Targeting the tumour microenvironment in platinum-resistant ovarian cancer
Cummings, M., Freer, C., & Orsi, N. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.007 · Cited by 71
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
Blessin, N. C., Li, W., Mandelkow, T., Jansen, H. L., Yang, C. H., Raedler, J. B., Simon, R., Büscheck, F., Dum, D., Luebke, A. M., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00601-4 · Cited by 78
“Several of these studies have suggested that the immune inflamed and immune excluded phenotypes tended towards a longer survival as compared to the immune desert phenotype [6, 8, 36, 50].”
BackgroundResultAmodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74
Regulation of antitumor immunity by inflammation-induced epigenetic alterations
Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 72
Li, X., Zhai, J., Shen, Y., Zhang, T., Wang, Y., He, Y., You, Q., & Shen, L. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03223-3 · Cited by 74
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Jiang, X., Wang, J., Zheng, X., Liu, Z., Zhang, X., Li, Y., Wilhelm, J., Cao, J., Huang, G., Zhang, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003960 · Cited by 71
Ferroptosis: Promising approach for cancer and cancer immunotherapy
Zheng, S., & Guan, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216152 · Cited by 76
Mengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Bensch, F., Smeenk, M. M., van Es, S. C., de Jong, J. R., Schroder, C. P., Oosting, S. F., Hooge, M. N. L., van Oordt, C. W. M. D. H., Brouwers, A. H., Boellaard, R., et al. (2018) · Theranostics · doi:10.7150/thno.26370 · Cited by 70
“Furthermore, as also engineered antibodies and other constructs like bispecific antibodies or antibody fragments with potentially different kinetics and dynamics are introduced in the clinics, more detailed information on distribution in combination with long term experience in dosing, side effects and efficacy of the…”
Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action
Take, Y., Koizumi, S., & Nagahisa, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00324 · Cited by 70
“from the tumor tissue is often observed in many cancers, and they are commonly referred to as non-T-cell-inflamed tumors (28).”
BackgroundSteenbrugge, J., Elst, N. V., Demeyere, K., Wever, O. D., Sanders, N. N., Broeck, W. V. D., Dirix, L. Y., Laere, S. V., & Meyer, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02928 · Cited by 78
“Moreover, as both 4T1 and Py230 tumors were infiltrated with TILs, and more specifically immunoreactive CD8a cytotoxic T-cells and CD4 T-helper cells, they can be classified as so called “hot” tumors (51).”
BackgroundToyoda, T., Kamata, T., Tanaka, K., Ihara, F., Takami, M., Suzuki, H., Nakajima, T., Ikeuchi, T., Kawasaki, Y., Hanaoka, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000316 · Cited by 72
Ma, T., Hu, C., Lal, B., Zhou, W., Ma, Y., Ying, M., Prinos, P., Quiñones‐Hinojosa, A., Lim, M. K., Laterra, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2489 · Cited by 67
“Tumor infiltration ofCD8þTcells is required to achievemeaningful therapeutic responses to immunotherapy (30, 31).”
BackgroundVara, B., Levi, S. M., Achab, A., Candito, D. A., Fradera, X., Lesburg, C. A., Kawamura, S., Lacey, B. M., Lim, J., Methot, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00096 · Cited by 67
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 71
Liu, D., Yang, X., & Wu, X.-Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663495 · Cited by 80
“Three major immune phenotypes have been proposed in cancer, namely the immune-inflamed, immune-excluded, and immune-desert phenotypes (10, 32).”
BackgroundXu, W., Liu, W., Xu, Y., Tian, X., Anwaier, A., Su, J., Zhu, W., Shi, G., Wei, G., Huang, Y., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58295 · Cited by 72
Gao, Y., Wang, H., Li, H., Ye, X., Xia, Y., Yuan, S., Lu, J., Xie, X., Wang, L., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1936758 · Cited by 75
“As reported in a previous study, the presence of abundant immune cells retained in the stroma surrounding tumor cell nests could activate the stroma of TME, thus suppressing adaptive immunity.(29) Therefore, we speculated that the activation of stroma in Cluster A inhibited the antitumor effect of immune cells.”
BackgroundTargeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma
Lin, M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y., & Lv, L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164528 · Cited by 72
“Evasion of immune surveillance is a hallmark of cancer (40).”
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
“This immunophenotype likely reflects the absence of pre-existing antitumor immunity, suggesting that tumor-specific T cell generation is the rate-limiting step (14).”
BackgroundInfluentialThe immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes
Kakizaki, M., Yamamoto, Y., Yabuta, S., Kurosaki, N., Kagawa, T., & Kotani, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205886 · Cited by 65
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 69
Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64
Self-citationIntratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype
Kim, T. S., da Silva, E. M., Coit, D. G., & Tang, L. H. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001253 · Cited by 73
“Age (median [range]) (y) 68 (20-92) 72 (40-85) 74 (55-85) 78 (52-92) 48 (20-67) < 0.”
Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy
Zhang, C., & Pu, K. (2020) · Small Structures · doi:10.1002/sstr.202000026 · Cited by 66
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern, E. S., Solomon, B., Hui, R., Pavlakis, N., O'Byrne, K. J., & Hughes, B. G. M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002248 · Cited by 70
Luginbuhl, A., Johnson, J. M., Harshyne, L. A., Linnenbach, A. J., Shukla, S. K., Alnemri, A. E., Kumar, G., Cognetti, D. M., Curry, J., Kotlov, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1816 · Cited by 70
“Therefore, escape mechanisms may develop early in tumor evolution in HPV+ HNSCC (33).”
BackgroundMolecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 80
“These tumors are considered as immunoreactive or “hot” tumors, while those that lack such TILs are termed “cold” tumors (13).”
BackgroundBian, J., Lin, J., Long, J., Xu, Y., Yang, X., Lu, X., Sang, X., & Zhao, H. (2020) · American Journal of Cancer Research · Cited by 81
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Liu, S.-Y., & Wu, Y.-L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0506-z · Cited by 63
“, mutational burden, smoking index, and neoantigen quantity) are very complicated [23, 24], and further research is needed.”
BackgroundTIM-3 expression in breast cancer
Burugu, S., Gao, D., Leung, S. C. Y., Chia, S., & Nielsen, T. O. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502128 · Cited by 72
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Qiu, Z., Chen, Z., Zhang, C., & Zhong, W. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0143-z · Cited by 65
“To our knowledge, through eliminating mutated cell, cytotoxic T lymphocyte (CTL) can prevent cancer’s development and progression [5].”
Backgroundm 6 A modification patterns and tumor immune landscape in clear cell renal carcinoma
Zhong, J., Liu, Z., Cai, C., Duan, X., Deng, T., & Zeng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001646 · Cited by 83
Huang, L., Wang, R., Xie, K., Zhang, J., Tao, F., Pi, C., Feng, Y., Gu, H., & Fang, J. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06384-4 · Cited by 67
Liu, R., Yang, F., Yin, J., Liu, Y., Zhang, W., & Zhou, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685370 · Cited by 77
“ICIs activate preexisting tumor-infiltrating lymphocytes, which recognize and eliminate dysplastic and neoplastic cells, contributing to the response to immunotherapy (13).”
BackgroundHiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 90
Zhao, J., Shen, J., Mao, L., Yang, T., Liu, J., & Hongbin, S. (2024) · Oncogene · doi:10.1038/s41388-024-03057-6 · Cited by 75
“However, cancer cells can evolve multiple strategies to limit or evade genetically controlled cell death, thereby accelerating cancer cell proliferation and malignant transformation [5, 7, 8].”
Xing, Y., Yang, J., Peng, A., Qian, Y., Liu, Y., Pan, P., & Liu, Q. (2024) · Advanced Materials · doi:10.1002/adma.202412730 · Cited by 69
Small-Molecule Targets in Immuno-Oncology
Dhanak, D., Edwards, J. P., Nguyen, A., & Tummino, P. J. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.019 · Cited by 67
“Chen and Mellman (2017) have described three tumor phenotypes that associate with patient response to IO agents, in which the ‘‘immune-inflamed’’ is more likely to respond, while the ‘‘immune-excluded’’ and ‘‘immune-desert’’ phenotypes have a high percentage of non-responders.”
BackgroundMethodJacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2019) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 64
Marcelis, L., Antoranz, A., Delsupehe, A.-M., Biesemans, P., Ferreiro, J. F., Debackere, K., Vandenberghe, P., Verhoef, G. E. G., Gheysens, O. S., Cattoretti, G., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02575-y · Cited by 72
“Apart from the number of cytotoxic T cells, also the functional status of CD8+ T cells plays a role in response to immunotherapy [18].”
BackgroundThe current landscape of single-cell transcriptomics for cancer immunotherapy
Guruprasad, P., Lee, Y. G., Kim, K. H., & Ruella, M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201574 · Cited by 66
Kelley, R. K., Oliver, J. W., Hazra, S., Benzaghou, F., Yau, T. C. C., Cheng, A., & Rimassa, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0283 · Cited by 65
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 69
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
“The paucity of T cells in both the periphery and the parenchyma of the tumour is indicative of TMEs that possess an immune-desert phenotype.”
BackgroundInfluential
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.